Ads
related to: cetuximab- 109 S High St #100, Columbus, OH · Directions · (614) 224-4261
Search results
Results from the WOW.Com Content Network
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .
Cetuximab: IV: EGFR inhibitor. Squamous cell head and neck cancer or EGFR-positive and KRAS wild-type metastatic colorectal cancer. Infusion-related reactions, skin reactions, hypomagnesaemia, hypocalcaemia, hypokalaemia, blood clots, interstitial lung disease and aseptic meningitis. Denosumab: SC: RANKL inhibitor.
Cetuximab is the first-line therapy for Ménétrier disease. [2] Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR), and has been shown to be effective in treating Ménétrier disease. [7] Several medications have been used in the treatment of the condition, with variable efficacy.
Cetuximab target the epidermal growth factor receptor . It is approved for use in the treatment of metastatic colorectal cancer [24] [25] and squamous cell carcinoma of the head and neck. [26] [27] Panitumumab also targets the EGFR. It is approved for the use in the treatment of metastatic colorectal cancer.
Cetuximab (trade name: Erbitux ) is a recombinant chimeric monoclonal antibody designed to treat metastatic colorectal cancer and head and neck cancer. [14] In numerous cancers, the epidermal growth factor receptor (EGFR) is often inappropriately activated and overexpressed in cancer cells, leading to uncontrolled cell growth. [15]
As of 2012, it was known that emergence of KRAS mutations was a frequent driver of acquired resistance to cetuximab anti-EGFR therapy in colorectal cancers. The emergence of KRAS mutant clones can be detected non-invasively [how?] months before radiographic progression.
Some targeted therapies used in head and neck cancers include cetuximab, bevacizumab, and erlotinib. [citation needed] Cetuximab is used for treating people with advanced-stage cancer who cannot be treated with conventional chemotherapy . [105] [106] However, cetuximab's efficacy is still under investigation by researchers. [107]
In July 2009, the FDA updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include information about KRAS mutations. [14] This was the result of a study, which demonstrated lack of benefit with Panitumumab in patients who carried NRAS mutations. [6]
Ads
related to: cetuximab- 109 S High St #100, Columbus, OH · Directions · (614) 224-4261
